Back to results

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY) (BQ5)

Primary Purpose

Ischemic Stroke

Status

Recruiting

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

BQ 2.0

About this trial

This is an interventional supportive care trial for Ischemic Stroke focused on measuring subacute

Eligibility Criteria

22 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

mRS score of 3 or 4.
FMA-UE score between 10-45 (inclusive) of impaired limb.
Age 22 to 85 years of age (inclusive).
Diagnosed with an ischemic stroke, confirmed by CT or MRI imaging.
4 to 21 days from stroke onset (or last known well).
Pre-stroke mRS of 0 or 1.
Able to sit with the investigational device for 40 consecutive minutes.
Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me".
Willingness to participate in occupational/physical therapy activities during study intervention sessions.
Availability of a relative or other caregiver able to assist during PT/OT treatment delivered via video call sessions during the study.
If female, not pregnant (as confirmed by a urine or a blood test, or as determined by an official medical document) or breastfeeding and with no ability to become pregnant or on an acceptable method of contraception during the study
Informed consent signed by subject (if competent) or legally authorized representative.

Exclusion Criteria:

Severe neglect impairment (NIHSS item 11 score = 2) or neglect that is severe enough to interfere with reasonable performance of study procedures. assessments or treatments.
Implanted active electronic or passive MR-incompatible devices.
Previous ischemic or hemorrhagic stroke within the 2 weeks before the index stroke.
Pre-existing neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or seizure in the last 5 years.
Significant visual disturbances that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
Unstable serious illness/condition (eg, active cancer, severe heart failure, active psychiatric condition) or life expectancy of less than 6 12 months.
A known severe allergic reaction to acrylic-based adhesives.
Ongoing alcohol abuse and/or illicit drug use.
Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.
Employee of the Sponsor.
Prisoner.

Sites / Locations

Ronald Reagan UCLA Medical Center & California Rehabilitation Institute
MedStar National Rehabililtaion Hospital,Recruiting
Brooks Rehabilitation Hospital - University CampusRecruiting
The Miami Project to Cure Paralysis
Shirley Ryan AbilitylabRecruiting
KU Medical CenterRecruiting
Spaulding Rehabilitation HospitalRecruiting
JFK Johnson Rehabilitation InstituteRecruiting
Kessler Institute of RehabilitationRecruiting
NYP Brooklyn Methodist Hospital Outpatient RehabilitationRecruiting
Atrium Health Carolinas RehabilitationRecruiting
Moss Rehabilitation Research Institute
Baylor Scott & White Institute for Rehabilitation
TIRR Memorial Hermann Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Active Comparator

Arm Label

BQ 2.0 sham stimulation group

BQ 2.0 active stimulation group

Arm Description

45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

Outcomes

Primary Outcome Measures

Change from Baseline in Modified Rankin Scale

Mean change in mRS score from baseline (post-stroke day 4-21) to 90 days post stroke (90 ±15 days post-stroke)

Secondary Outcome Measures

Change from Baseline in Fugl-Meyer Assessment for Upper Extremity (upper limb function)

Lead secondary endpoint: Fugl-Meyer Assessment for Upper Extremity (upper limb function) - to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

Change from Baseline in Box and Block Test (fine hand function)

Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

Change from Baseline in 10 Meter Walk Test (gait speed)

Secondary Endpoint: To show the BQ therapy is effective in reducing lower limb imperement

Change from baseline in Stroke Impact Scale Hand Domain (patient-reported hand function)

Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

Change from baseline in Stroke Impact Scale 16 (patient-reported physical functional limitation)

Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

Change from baseline in 5-level EQ-5D (health-related quality of life)

Secondary Endpoint: To show that the BQ therapy is effective in improving health-related quality of life (HRQoL)

Full Information

NCT ID

NCT05044507

First Posted

August 4, 2021

Last Updated

February 23, 2023

Sponsor

BrainQ Technologies Ltd.

1. Study Identification

Unique Protocol Identification Number

NCT05044507

Brief Title

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)

Acronym

BQ5

Official Title

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)

Study Type

Interventional

2. Study Status

Record Verification Date

August 2022

Overall Recruitment Status

Recruiting

Study Start Date

December 4, 2021 (Actual)

Primary Completion Date

December 31, 2023 (Anticipated)

Study Completion Date

March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

BrainQ Technologies Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Yes

Device Product Not Approved or Cleared by U.S. FDA

Yes

Product Manufactured in and Exported from the U.S.

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. In this study, BQ 2.0 is intended to reduce disability in adult patients with subacute ischemic stroke, with a moderate to severe disability which includes an upper extremity motor impairment. BQ 2.0 will be used for 9 weeks in conjunction with physical and occupational therapy (PT/OT) and periodic supervision (either remote or in person) of a trained site study team member. Treatments may be administered in multiple settings (e.g. acute care hospital (ACH) or inpatient rehabilitation facilities (IRF), Skilled Nursing Facility (SNF), home or other outpatient setup). The study will enroll up to 150 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using BQ 2.0.

Detailed Description

The study intervention will be initiated 4-21 days after the index stroke event and will consist of a total of 45 sessions over a period of 9 weeks (5 treatments per week). Each session will last 60 minutes during which 40 net minutes of active or sham study intervention using BQ 2.0 will be administered. Each study group will receive a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention. Screening phase: Prospective subjects, who are 3 to 21 days post-stroke, will be consented to participate in the study at either: a participating initial acute care hospital (ACH), prior to anticipated transfer to a participating IRF, SNF, Outpatient or home setting or at a participating IRF, SNF, outpatient or home setting Consented subjects, who are 4 to 21 days post-stroke will be screened for eligibility to participate in the treatment phase of the study. Eligible subjects will be randomly assigned, at a 1:1 allocation ratio, to either the active or sham study intervention groups. Treatment and follow-up Randomized patients will proceed to the treatment phase of the study. Active or sham study intervention sessions using BQ 2.0 (active or sham therapy, respectively) will be conducted 5 times a week, starting 4-21 days after stroke onset and no later than 2 days after randomization. Each session will last 60 minutes, with active or sham field being turned on for up to 40 minutes. The only difference between the BQ 2.0 active stimulation and sham therapy is that the sham device does not generate electromagnetic fields during treatment. Subjects in both the active intervention group (BQ 2.0 group) and sham group will be asked to perform device guided physical and occupational therapy activities during each session. Participation in the study will not replace any of usual care patient should recieve. Subjects will undergo a detailed interim outcome assessment on the 20th (±4) day of treatment and a detailed primary endpoint outcome assessment on the 90th (±15) day after the onset of the index stroke. In addition, a focused, long-term outcome assessment on the 180th (±15) day after the onset of the index stroke will be performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Ischemic Stroke

Keywords

subacute

7. Study Design

Primary Purpose

Supportive Care

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Model Description

subjects will be assigned (1:1 allocation ratio) to either active or sham study intervention using BQ 2.0

Masking

ParticipantCare ProviderInvestigator

Masking Description

This is a double-blind study, subjects and Investigators will be blinded to the device setting (Active/Sham). The study site team members receiving, storing, dispensing, preparing, and administering the study interventions will be blinded. Subjects' caregivers will also be blinded. There are no differences in the active and sham device appearance. Due to the non-invasive nature of the treatment, as well as the physical characteristic of the EMF, there is no noticeable difference between sessions conducted using an active or a sham device, facilitating full blinding of both subjects and Investigators. An independent unblinded statistician (not the study statistician) will perform the assessments described. Only the unblinded statistician and members of the DSMB will be exposed to the interim report.

Allocation

Randomized

Enrollment

150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

BQ 2.0 sham stimulation group

Arm Type

Sham Comparator

Arm Description

Arm Title

BQ 2.0 active stimulation group

Arm Type

Active Comparator

Arm Description

Intervention Type

Device

Intervention Name(s)

BQ 2.0

Other Intervention Name(s)

BQ 2.0 sham stimulation group

Intervention Description

frequency and intensity parameters will be set to zero so that no stimulation is delivered

Intervention Type

Device

Intervention Name(s)

BQ 2.0

Other Intervention Name(s)

BQ 2.0 active stimulation group

Intervention Description

The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Primary Outcome Measure Information:

Title

Change from Baseline in Modified Rankin Scale

Description

Mean change in mRS score from baseline (post-stroke day 4-21) to 90 days post stroke (90 ±15 days post-stroke)

Time Frame

change from baseline (4-21 days post stroke) to 90 days post stroke. mRS will be assessed at 90 Day FU visit

Secondary Outcome Measure Information:

Title

Change from Baseline in Fugl-Meyer Assessment for Upper Extremity (upper limb function)

Description

Time Frame

change from baseline (4-21 days post stroke) to 90 days post stroke. FMA-EU will be assessed at 90 Day FU visit

Title

Change from Baseline in Box and Block Test (fine hand function)

Description

Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

Time Frame

change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed at 90 Day FU visit)

Title

Change from Baseline in 10 Meter Walk Test (gait speed)

Description

Secondary Endpoint: To show the BQ therapy is effective in reducing lower limb imperement

Time Frame

change from baseline (4-21 days post stroke) to 90 days post stroke. (will be assessed at 90 Day FU visit )

Title

Change from baseline in Stroke Impact Scale Hand Domain (patient-reported hand function)

Description

Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

Time Frame

change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed at 90 Day FU visit )

Title

Change from baseline in Stroke Impact Scale 16 (patient-reported physical functional limitation)

Description

Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

Time Frame

change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed on 90 Day FU visit )

Title

Change from baseline in 5-level EQ-5D (health-related quality of life)

Description

Secondary Endpoint: To show that the BQ therapy is effective in improving health-related quality of life (HRQoL)

Time Frame

Change from baseline (4-21 days post-stroke) to 90 days post-stroke (will be assessed on 90 Day FU visit )

Other Pre-specified Outcome Measures:

Title

Serious procedure or device related adverse events & device deficiencies

Description

Safety: To characterize the safety profile of the BQ therapy and to show that the BQ 2.0 performs reliably.

Time Frame

Through study completion, an average of 90 ± 15 days post-stroke (will be assessed on 90 Day FU visit )

Title

Change in Montreal Cognitive Assessment (global cognitive function)

Description

Tertiary/Exploratory: To show that the BQ therapy is effective in reducing cognitive impairment at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.

Time Frame

will be assessed at 90 Day FU visit

Title

Change in Patient Health Questionnaire-8 (depression)

Description

Tertiary/Exploratory: To show that the BQ therapy is effective in reducing depression at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.

Time Frame

will be assessed on 90 Day FU visit

Title

Change in Academic Medical Center Linear Disability Scale (granular level of disability) at 90 days post-stroke.

Description

Tertiary/Exploratory: To show that the BQ therapy is effective in reducing fine-grained level of disability at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.

Time Frame

will be assessed on 90 Day FU visit

Title

Change from Baseline in Modified Rankin Scale (global disability)

Description

Tertiary/Exploratory: To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on upper limb functionality

Time Frame

change from baseline (4-21 days post-stroke) to 180 days post-stroke. will be assessed at 6 month FU visit

Title

Change from Baseline in Stroke Impact Scale Hand Domain (patient-reported hand function)

Description

Tertiary/Exploratory: To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on upper limb functionality

Time Frame

change from baseline (4-21 days post-stroke) to 180 days post-stroke will be assessed at 6 month FU visit

Title

Change from Baseline in 5-level EQ-5D (health-related quality of life) at 180 days post-stroke.

Description

Tertiary/Exploratory:To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on health-related quality of life (HRQoL).

Time Frame

change from baseline (4-21 days post-stroke) to 180 days post-stroke (will be assessed at 6 month FU visit )

Title

Formal cost-effectiveness analysis over a lifetime horizon from the perspective of the United States healthcare system.

Description

Tertiary/Exploratory: To formally evaluate the cost-effectiveness of the BQ therapy over a lifetime horizon from the perspective of the United States healthcare system.

Time Frame

Will be assessed at 90 day FU visit and 6 month FU visit

Title

adherence to treatment as measured by the Qompass

Description

To explore the relationship between adherence to treatment as measured by the Qompass

Time Frame

Will be assessed upon data base lock

10. Eligibility

Sex

All

Minimum Age & Unit of Time

22 Years

Maximum Age & Unit of Time

80 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: mRS score of 3 or 4. FMA-UE score between 10-45 (inclusive) of impaired limb. Age 22 to 85 years of age (inclusive). Diagnosed with an ischemic stroke, confirmed by CT or MRI imaging. 4 to 21 days from stroke onset (or last known well). Pre-stroke mRS of 0 or 1. Able to sit with the investigational device for 40 consecutive minutes. Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me". Willingness to participate in occupational/physical therapy activities during study intervention sessions. Availability of a relative or other caregiver able to assist during PT/OT treatment delivered via video call sessions during the study. If female, not pregnant (as confirmed by a urine or a blood test, or as determined by an official medical document) or breastfeeding and with no ability to become pregnant or on an acceptable method of contraception during the study Informed consent signed by subject (if competent) or legally authorized representative. Exclusion Criteria: Severe neglect impairment (NIHSS item 11 score = 2) or neglect that is severe enough to interfere with reasonable performance of study procedures. assessments or treatments. Implanted active electronic or passive MR-incompatible devices. Previous ischemic or hemorrhagic stroke within the 2 weeks before the index stroke. Pre-existing neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or seizure in the last 5 years. Significant visual disturbances that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation. Unstable serious illness/condition (eg, active cancer, severe heart failure, active psychiatric condition) or life expectancy of less than 6 12 months. A known severe allergic reaction to acrylic-based adhesives. Ongoing alcohol abuse and/or illicit drug use. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur. Employee of the Sponsor. Prisoner.

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Assaf Lifshitz

Phone

972 54 4586787

assaf@brainqtech.com

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Jeffrey L Saver, MD

Organizational Affiliation

Lead Coordinating PI

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Pamela W Duncan, PhD

Organizational Affiliation

Lead Coordinating PI

Official's Role

Principal Investigator

Facility Information:

Facility Name

Ronald Reagan UCLA Medical Center & California Rehabilitation Institute

City

Los Angeles

State/Province

California

ZIP/Postal Code

90095

Country

United States

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Gilda Avila

GAvila@mednet.ucla.edu

First Name & Middle Initial & Last Name & Degree

Mersedeh Bahr Hosseini, MD

First Name & Middle Initial & Last Name & Degree

Michael Su, MD

Facility Name

MedStar National Rehabililtaion Hospital,

City

Washington

State/Province

District of Columbia

ZIP/Postal Code

20010

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Kathaleen Brady

Kathaleen.P.Brady@medstar.net

First Name & Middle Initial & Last Name & Degree

Richard Zorowitz, MD

Facility Name

Brooks Rehabilitation Hospital - University Campus

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32216

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Hannah, MS, ACSM-EP

Hannah.Snyder@Brooksrehab.org

First Name & Middle Initial & Last Name & Degree

Emily Fox

Facility Name

The Miami Project to Cure Paralysis

City

Miami

State/Province

Florida

ZIP/Postal Code

33136

Country

United States

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Iszet Campo-Bustillo

Phone

305-243-8018

icampo@med.miami.edu

First Name & Middle Initial & Last Name & Degree

Ning Cao, MD

Facility Name

Shirley Ryan Abilitylab

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60611

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sara J Prokup, PT, DPT

sprokup@ricres.org

First Name & Middle Initial & Last Name & Degree

Eliot Roth, MD

Facility Name

KU Medical Center

City

Kansas City

State/Province

Kansas

ZIP/Postal Code

66160

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sasha Moors

smoores@kumc.edu

First Name & Middle Initial & Last Name & Degree

Sandra Billinger, PT, PhD,FAHA

Facility Name

Spaulding Rehabilitation Hospital

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02129

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jenny Min

bq5@partners.org

First Name & Middle Initial & Last Name & Degree

Randie Black-Schaffer, MD

Facility Name

JFK Johnson Rehabilitation Institute

City

Edison

State/Province

New Jersey

ZIP/Postal Code

08820

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Maria Belen Montealegre, OTD

Phone

(732) 321-7000

Ext

62853

maria.montealegre@hmhn.org

First Name & Middle Initial & Last Name & Degree

Sara J Cuccurullo, MD

Facility Name

Kessler Institute of Rehabilitation

City

West Orange

State/Province

New Jersey

ZIP/Postal Code

07052

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Ghaith Androwis, Ph.D.

Phone

973-324-3565

gandrowis@kesslerfoundation.org

First Name & Middle Initial & Last Name & Degree

Steven Kirshblum, MD

Facility Name

NYP Brooklyn Methodist Hospital Outpatient Rehabilitation

City

Brooklyn

State/Province

New York

ZIP/Postal Code

11215

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Joy J Rutherford

Phone

718-780-7715

jor9147@nyp.org

First Name & Middle Initial & Last Name & Degree

Joel Stein, MD

Facility Name

Atrium Health Carolinas Rehabilitation

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28203

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Tami Guerrier

Tami.Guerrier@atriumhealth.org

First Name & Middle Initial & Last Name & Degree

Matthew Shall, MD

Facility Name

Moss Rehabilitation Research Institute

City

Elkins Park

State/Province

Pennsylvania

ZIP/Postal Code

19027

Country

United States

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Grace Loscalzo

CaoNing1@einstein.edu

First Name & Middle Initial & Last Name & Degree

Ning Chao, MD

Facility Name

Baylor Scott & White Institute for Rehabilitation

City

Dallas

State/Province

Texas

ZIP/Postal Code

75246

Country

United States

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Lacy Mcdonald

LACY.MCDONALD@BSWHEALTH.ORG

First Name & Middle Initial & Last Name & Degree

Simon Driver, PhD

Facility Name

TIRR Memorial Hermann Hospital

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Emily Stevens, OTR

Emily.A.Stevens@uth.tmc.edu

First Name & Middle Initial & Last Name & Degree

Sean Savitz, MD

12. IPD Sharing Statement

Learn more about this trial

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)

We'll reach out to this number within 24 hrs